[2] COVID-19 infection and mortality tracking in the US and around the world

This section analyzes COVID infections and mortality reported to local, federal and intergovernmental agencies, and are heavily influenced by testing rates and differences in government reporting standards and capabilities. As we explain in Section 5, serology tests suggest that the true number of COVID infections may be 10x-20x higher than the number of reported infections. However, trends in reported infections are still important to monitor, since they influence government policy and the behavior of citizens and companies.

Table of contents
1. What’s new: a look at recent notable changes in infection and mortality ................................................................. 2
2. Summary of global and US infection/mortality trends .................................................................................................................. 3
3. COVID at a glance (countries and US states), and the reasons for falling mortality trends ......................................................... 4
4. Infections and mortality snapshots: current vs peak levels of infection and mortality ........................................................... 5
5. Global and US infection and mortality threshold levels ............................................................................................................... 7
6. US hotspot infection, hospitalization and mortality tracking ..................................................................................................... 8
7. Country level infection, hospitalization and mortality trends .................................................................................................. 11

Comments on Africa data. In part 7, several countries show up with almost no COVID outbreak reported. In cases like New Zealand, Taiwan, Japan, Vietnam and South Korea, we interpret the lack of a material outbreak as possible based on the quality of data reporting and testing taking place. Other countries which report practically no material incidence of COVID include Nigeria, Kenya, Angola, DR Congo, Tanzania and Mozambique. According to various news reports¹, there’s a shortage of reliable data in many of these countries, and the lack of funds to carry out broad scale testing. On the other hand, while infections can be obscured, it’s harder to obscure a sharp rise in mortality; even when accounting for some under-reporting of deaths, Africa mortality rates are still much lower than expected. The few antibody surveys conducted in Africa reveal COVID prevalence that is similar to other European countries; in other words, COVID is spreading in Africa as it is elsewhere. The most likely explanation for lower relative mortality is age: Africa’s median age is 18, compared to 35 in North America and 42 in Europe. Since those over age 65 experience 80% of COVID mortality, age distributions are the most likely reason for lower African COVID mortality rates.

Additional supplementary materials are available upon request: COVID mortality distributions and probabilities by age bracket and US state, COVID mortality per mm vs Case Fatality Rates by country and US state, and COVID infections by age group by US state.

On data sources. We generally use infection and mortality data from Johns Hopkins, with any exceptions noted in chart sources. While JHU data usually match sources such as covidtracking.com and Worldometers, this is not always the case. Any large differences usually work themselves out over time; even so, such differences are a warning against over-extrapolating any short term trends seen in the data. There are also patterns in some countries in which tests and infections drop over the weekend, only to rise the following week. Other anomalies: countries and US states sometimes make large one-time additions or subtractions to infections or deaths data to reflect over- or underestimations made over the course of the entire pandemic. JHU and other data providers do not amortize such adjustments over time and simply reflect them on the day they are made; we do the same.

What’s new: Northeast US, Europe, Latin America, etc

- “Big Sky” US states are experiencing infection levels that are around 5x higher than adjacent Canadian provinces. The Northeastern US is now experiencing a material rise in infections as well after a very quiet summer.
- The US positive testing rate is rising more slowly than infections, suggesting that a rise in testing explains many new infections; the opposite is true in most of Europe, where testing only explains a small part of the spike.
- The increase in infections in Western Europe surpasses Spring levels; hospitalization and mortality levels are now starting to rise as well.
- Infections in many Latin American countries are rolling over now from very high levels.
Summary of global and US infection/mortality trends

World daily infections vs mortality

![World daily infections vs mortality chart](chart1)

Source: JHU, JPMAM. 11/09/2020. 7 day avg.

US daily infections vs mortality

![US daily infections vs mortality chart](chart2)

Source: JHU, COVID Tracking, JPMAM. 11/09/2020. 7 day avg.

Dev World ex-US daily infections vs mortality

![Dev World ex-US daily infections vs mortality chart](chart3)

Source: JHU, JPMAM. 11/09/2020. 7 day avg.

S America daily infections vs mortality

![S America daily infections vs mortality chart](chart4)

Source: JHU, JPMAM. 11/09/2020. 7 day avg.

US vs Europe infections

New daily infections per mm people, 7 day avg

![US vs Europe infections chart](chart5)

Source: Johns Hopkins University, IMF, JPMAM. November 09, 2020

US vs Europe mortality

Daily deaths per mm people, 7 day avg

![US vs Europe mortality chart](chart6)

Source: Johns Hopkins University, IMF, JPMAM. November 09, 2020
COVID at a glance: infections and mortality per mm, and the falling age of infected persons

COVID at a glance: trailing 7 day infection and mortality per mm

Mortality per mm, 7 day average

States not shown since they are off the chart: WI IA SD ND
Countries not shown since they are off the chart: CZE BEL

Lower mortality rates in the developed world

Lower mortality rates in the developed world (when compared to the spring of 2020) appear to reflect the lower age of more recently infected persons, less overcrowded hospitals, and more informed standards of patient care (less unnecessary ventilation when oxygenation will suffice, and the use of steroids and blood thinners).

The charts below show shifting COVID patient age levels for the US and Switzerland. In Section 4, see pages 6–7 for a discussion of the empirically measured benefits of steroids like dexamethasone and of anti-coagulants and other blood thinners.

Median age of individuals with positive SARS-CoV-2 PCR test results, Years

Source: CDC. October 2020.

Switzerland first wave vs second wave

Distribution of COVID infections by age group

Infections and mortality snapshots: current vs peak levels of infection and mortality

The two charts below show peak and current levels of infection (top chart) and mortality (bottom chart) for the 50 largest countries in the world based on GDP. These countries represent 94% of global GDP.

Source: Johns Hopkins University, IMF, JPMAM. Countries shown represent 94% of World GDP. November 09, 2020.
The three charts below show peak and current levels of infection (first chart), mortality (second chart) and the positive testing rate (third chart) for the 50 US states and DC.

**Infection levels for US states: peak vs current**
Sorted by trailing 7 day average infection rate per mm people

Legend:
- Peak infection rate per mm
- Latest infection rate per mm

Source: Johns Hopkins University, IMF, JPMAM. November 09, 2020

**Mortality levels for US states: peak vs current**
Sorted by trailing 7 day average mortality rate per mm people

Legend:
- Peak mortality rate per mm
- Latest mortality rate per mm

Source: Johns Hopkins University, IMF, JPMAM. November 09, 2020

**Positive testing rate for US states**
Sorted by trailing 14 day average positive testing rate

Global and US infection and mortality threshold levels

The charts below track the percentages of the global and US economy with infection and mortality levels that surpass indicated thresholds. The geographical units are countries for the global economy, and states for the US economy.

**Global COVID infection thresholds**

% of global GDP exceeding indicated threshold

Source: JHU, JPMAM. 11/09/2020. 7 day averages.

**Global COVID mortality thresholds**

% of global GDP exceeding indicated threshold

Source: JHU, JPMAM. 11/09/2020. 7 day averages.

**US COVID infection thresholds**

% of US GDP exceeding indicated threshold

Source: Covid Tracking, JPMAM. 11/09/2020. 7 day averages.

**US COVID mortality thresholds**

% of US GDP exceeding indicated threshold

Source: JHU, JPMAM. 11/09/2020. 7 day averages.
US hotspot infection, hospitalization and mortality tracking

The charts below track infection, hospitalization, testing, mortality and doctor visit data for the US in aggregate and for US infection hotspots. See section 6 for a state-by-state chartpack which covers the full range of infection, mortality, hospitalization, testing and hospital utilization data.

---

2 We dynamically define hotspot states in three ways: the largest one-month increase in new daily infections per mm people, the highest levels of infection and the highest rates of positive PCR testing. If a state shows up as top 7 on any of these 3 metrics, they are included as a hotspot.
**Hotspots: ID IL IA KS MN MT NE ND SD WI WY**

New daily infections per mm

Source: COVID Tracking, CMU, JPMAM. 11/9/2020. 7 day avgs.

**United States virus tracking**

New daily infections per mm

Source: COVID Tracking, CMU, JPMAM. 11/9/2020. 7 day avgs.

**Infections by state category**

US new daily infections per mm people, 7 day avg

Source: Johns Hopkins University, IMF, JPMAM. November 09, 2020

**Hospitalizations by state category**

US current hospitalizations per mm people, 7 day avg

Source: COVID Tracking Project, IMF, JPMAM. November 09, 2020

**Mortality by state category**

US daily deaths per mm people, 7 day avg

Source: Johns Hopkins University, IMF, JPMAM. November 09, 2020

**Testing by state category**

US daily tests per mm people, 7 day avg

Source: Johns Hopkins University, IMF, JPMAM. November 09, 2020
Why aren’t US infections declining more rapidly?

The US does not have internal border controls; as a result, focusing too much on infections at the state level ignores the ease with which US citizens cross state lines. As shown below, former Hotspot states have now transmitted the infection to new Hotspot states.

**Without border controls, Hotspots keep shifting**

Source: JHU, JPMAM. November 9, 2020.
Country level infection, hospitalization and mortality trends

This section contains infection, hospitalization and mortality trends for the 68 countries that are among the Top 50 Countries by GDP, or among the Top 50 Countries by Population. The country charts appear in descending order of GDP, and are all scaled relative to Europe for comparability purposes. Note that high frequency hospitalization data is only available for a subset of the countries below.
Singapore daily infections vs mortality

Malaysia daily infections vs mortality

Philippines daily infections vs mortality

South Africa daily infections vs mortality

Denmark daily infections vs mortality

Vietnam daily infections vs mortality

Colombia daily infections vs mortality

Egypt daily infections vs mortality

Bangladesh daily infections vs mortality

Pakistan daily infections vs mortality

Finland daily infections vs mortality

Source: JHU, JPMAM. 11/09/2020. 7 day avg.

Source: JHU, JPMAM. 11/09/2020. 7 day avg.

Source: JHU, ECDC, JPMAM. 11/09/2020. 7 day avg.

Source: JHU, JPMAM. 11/09/2020. 7 day avg.

Source: JHU, JPMAM. 11/09/2020. 7 day avg.

Source: JHU, JPMAM. 11/09/2020. 7 day avg.

Source: JHU, JPMAM. 11/09/2020. 7 day avg.

Source: JHU, JPMAM. 11/09/2020. 7 day avg.

Source: JHU, JPMAM. 11/09/2020. 7 day avg.

Source: JHU, JPMAM. 11/09/2020. 7 day avg.

Source: JHU, JPMAM. 11/09/2020. 7 day avg.

Source: JHU, JPMAM. 11/09/2020. 7 day avg.

Source: JHU, JPMAM. 11/09/2020. 7 day avg.

Source: JHU, JPMAM. 11/09/2020. 7 day avg.

Source: JHU, JPMAM. 11/09/2020. 7 day avg.

Source: JHU, JPMAM. 11/09/2020. 7 day avg.

Source: JHU, JPMAM. 11/09/2020. 7 day avg.

Source: JHU, JPMAM. 11/09/2020. 7 day avg.
Angola daily infections vs mortality
Source: JHU, JPMAM. 11/09/2020. 7 day avg.

Algeria daily infections vs mortality
Source: JHU, JPMAM. 11/09/2020. 7 day avg.

New Zealand daily infections vs mortality
Source: JHU, JPMAM. 11/09/2020. 7 day avg.

Peru daily infections vs mortality
Source: JHU, ECDC, JPMAM. 11/09/2020. 7 day avg.

Ethiopia daily infections vs mortality
Source: JHU, JPMAM. 11/09/2020. 7 day avg.

Morocco daily infections vs mortality
Source: JHU, ECDC, JPMAM. 11/09/2020. 7 day avg.

Czechia daily infections vs mortality
Source: JHU, ECDC, JPMAM. 11/09/2020. 7 day avg.

Kenya daily infections vs mortality
Source: JHU, JPMAM. 11/09/2020. 7 day avg.

Ukraine daily infections vs mortality
Source: JHU, JPMAM. 11/09/2020. 7 day avg.

Mortgage
Source: JHU, JPMAM. 11/09/2020. 7 day avg.

Morocco daily infections vs mortality
Source: JHU, ECDC, JPMAM. 11/09/2020. 7 day avg.

Ethiopia daily infections vs mortality
Source: JHU, JPMAM. 11/09/2020. 7 day avg.

Angola daily infections vs mortality
Source: JHU, JPMAM. 11/09/2020. 7 day avg.
regulated by the Commission de Surveillance du Secteur Financier (CSSF) and jointly supervised by the European Central Bank (ECB) and the CSSF in Luxembourg; J.P. Morgan Bank Luxembourg S.A., Amsterdam Branch is also authorised and supervised by De Nederlandsche Bank (DNB) and the Autoriteit Financiële Markten (AFM) in the Netherlands. Registered with the Kamer van Koophandel as a branch of J.P. Morgan Bank Luxembourg S.A. under registration number 71651845. In Denmark, this material is distributed by J.P. Morgan Bank Luxembourg, Copenhagen Br, filial af J.P. Morgan Bank Luxembourg S.A. with registered office at Kalvebod Brygge 39-41, 1560 København V, Denmark. J.P. Morgan Bank Luxembourg, Copenhagen Br, filial af J.P. Morgan Bank Luxembourg S.A. is authorised and regulated by Commission de Surveillance du Secteur Financier (CSSF) and jointly supervised by the European Central Bank (ECB) and the CSSF. J.P. Morgan Bank Luxembourg, Copenhagen Br, filial af J.P. Morgan Bank Luxembourg S.A. is also subject to the supervision of Finanstilsynet (Danish FSA) and registered with Finanstilsynet as a branch of J.P. Morgan Bank Luxembourg S.A. under code 29009. In Sweden, this material is distributed by J.P. Morgan Bank Luxembourg S.A. – Stockholm Bankfilial, with registered office at Hamngatan 15, Stockholm, 11147, Sweden. J.P. Morgan Bank Luxembourg S.A. – Stockholm Bankfilial is authorised and regulated by Commission de Surveillance du Secteur Financier (CSSF) and jointly supervised by the European Central Bank (ECB) and the CSSF. J.P. Morgan Bank Luxembourg, Copenhagen Br, filial af J.P. Morgan Bank Luxembourg S.A. is also subject to the supervision of Finansinspektionen (Swedish FSA). Registered with Finansinspektionen as a branch of J.P. Morgan Bank Luxembourg S.A. In France, this material is distributed by JPMorgan Chase Bank, N.A. (“JPMCB”), Paris branch, which is regulated by the French banking authorities Autorité de Contrôle Prudentiel et de Résolution and Autorité des Marchés Financiers. In Switzerland, this material is distributed by J.P. Morgan (Suisse) SA, which is regulated in Switzerland by the Swiss Financial Market Supervisory Authority (FINMA).

In Hong Kong, this material is distributed by JPMC, Hong Kong branch. JPMC, Hong Kong branch is regulated by the Hong Kong Monetary Authority and the Securities and Futures Commission of Hong Kong. In Hong Kong, we will cease to use your personal data for our marketing purposes without charge if you so request. In Singapore, this material is distributed by JPMC, Singapore branch. JPMC, Singapore branch is regulated by the Monetary Authority of Singapore. Dealing and advisory services and discretionary investment management services are provided to you by JPMC, Hong Kong/Singapore branch (as notified to you). Banking and custody services are provided to you by JPMC Singapore Branch. The contents of this document have not been reviewed by any regulatory authority in Hong Kong, Singapore or any other jurisdictions. This advertisement has not been reviewed by the Monetary Authority of Singapore. JPMorgan Chase Bank, N.A., a national banking association chartered under the laws of the United States, and as a body corporate, its shareholder’s liability is limited.

JPMorgan Chase Bank, N.A. (JPMCNA) [ABN 43 074 112 011/AFS Licence No: 238367] is regulated by the Australian Securities and Investment Commission and the Australian Prudential Regulation Authority. Material provided by JPMCNA in Australia is to “wholesale clients” only. For the purposes of this paragraph the term “wholesale client” has the meaning given in section 761G of the Corporations Act 2001 (Cth). Please inform us if you are not a Wholesale Client now or if you cease to be a Wholesale Client at any time in the future.

JPM is a registered foreign company (overseas) (ABRN 109293610) incorporated in Delaware, U.S.A. Under Australian financial services licensing requirements, carrying on a financial services business in Australia requires a financial service provider, such as J.P. Morgan Securities LLC (JPM), to hold an Australian Financial Services Licence (AFSL), unless an exemption applies. JPM is exempt from the requirement to hold an AFSL under the Corporations Act 2001 (Cth) (Act) in respect of financial services it provides to you, and is regulated by the SEC, FINRA and CFTC under US laws, which differ from Australian laws. Material provided by JPM in Australia is to “wholesale clients” only. The information provided in this material is not intended to be, and must not be, distributed or passed on, directly or indirectly, to any other class of persons in Australia. For the purposes of this paragraph the term “wholesale client” has the meaning given in section 761G of the Act. Please inform us immediately if you are not a Wholesale Client now or if you cease to be a Wholesale Client at any time in the future.

This material has not been prepared specifically for Australian investors. It:
- may contain references to dollar amounts which are not Australian dollars;
- may contain financial information which is not prepared in accordance with Australian law or practices;
- may not address risks associated with investment in foreign currency denominated investments; and
- does not address Australian tax issues.

With respect to countries in Latin America, the distribution of this material may be restricted in certain jurisdictions. We may offer and/or sell to you securities or other financial instruments which may not be registered under, and are not the subject of a public offering under, the securities or other financial regulatory laws of your home country. Such securities or instruments are offered and/or sold to you on a private basis only. Any communication by us to you regarding such securities or instruments, including without limitation the delivery of a prospectus, term sheet or other offering document, is not intended by us as an offer to sell or a solicitation of an offer to buy any securities or instruments in any jurisdiction in which such an offer or a solicitation is unlawful. Furthermore, such securities or instruments may be subject to certain regulatory and/or contractual restrictions on subsequent transfer by you, and you are solely responsible for ascertaining and complying with such restrictions. To the extent this content makes reference to a fund, the Fund may not be publicly offered in any Latin American country, without previous registration of such fund’s securities in compliance with the laws of the corresponding jurisdiction. Public offering of any security, including the shares of the Fund, without previous registration at Brazilian Securities and Exchange Commission–CVM is completely prohibited. Some products or services contained in the materials might not be currently provided by the Brazilian and Mexican platforms.

References to “J.P. Morgan” are to JPM, its subsidiaries and affiliates worldwide. “J.P. Morgan Private Bank” is the brand name for the private banking business conducted by JPM.

This material is intended for your personal use and should not be circulated to or used by any other person, or duplicated for non-personal use, without our permission. If you have any questions or no longer wish to receive these communications, please contact your J.P. Morgan representative.

© 2020 JPMorgan Chase & Co. All rights reserved.